Key Points
- Lexeo Therapeutics CEO Richard Nolan Townsend sold 3,342 shares at an average price of $5.06, totaling $16,910.52, and said the sale was to cover tax withholding tied to vesting equity awards.
- The stock was trading up 14.3% and opened at $5.12, while the company’s market cap stood at about $402 million; shares remain well below the 12-month high of $10.99.
- Lexeo recently reported a smaller-than-expected quarterly loss of $0.25 per share versus estimates of $0.29, and analysts currently have a consensus Moderate Buy rating with an average target price of $18.88.
Lexeo Therapeutics, Inc. (NASDAQ:LXEO - Get Free Report) CEO Richard Nolan Townsend sold 3,342 shares of the business's stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $5.06, for a total transaction of $16,910.52. Following the sale, the chief executive officer directly owned 336,764 shares of the company's stock, valued at $1,704,025.84. This represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Richard Nolan Townsend also recently made the following trade(s):
- On Monday, April 6th, Richard Nolan Townsend sold 55,000 shares of Lexeo Therapeutics stock. The stock was sold at an average price of $5.69, for a total transaction of $312,950.00.
Lexeo Therapeutics Trading Up 14.3%
Shares of NASDAQ LXEO opened at $5.12 on Thursday. Lexeo Therapeutics, Inc. has a 12-month low of $2.51 and a 12-month high of $10.99. The stock has a market cap of $402.02 million, a PE ratio of -3.53 and a beta of 1.52. The company has a 50-day moving average of $5.96 and a 200 day moving average of $7.56.
Lexeo Therapeutics (NASDAQ:LXEO - Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.25) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.04. On average, sell-side analysts forecast that Lexeo Therapeutics, Inc. will post -1.19 EPS for the current fiscal year.
Institutional Trading of Lexeo Therapeutics
Hedge funds have recently made changes to their positions in the company. Allworth Financial LP grew its stake in shares of Lexeo Therapeutics by 1,002.9% in the 4th quarter. Allworth Financial LP now owns 3,386 shares of the company's stock valued at $34,000 after buying an additional 3,079 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Lexeo Therapeutics by 69.9% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,547 shares of the company's stock valued at $35,000 after buying an additional 1,459 shares during the period. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Lexeo Therapeutics in the 4th quarter valued at approximately $37,000. California State Teachers Retirement System grew its stake in shares of Lexeo Therapeutics by 123.7% in the 4th quarter. California State Teachers Retirement System now owns 3,884 shares of the company's stock valued at $39,000 after buying an additional 2,148 shares during the period. Finally, Russell Investments Group Ltd. grew its stake in shares of Lexeo Therapeutics by 160.2% in the 4th quarter. Russell Investments Group Ltd. now owns 5,872 shares of the company's stock valued at $58,000 after buying an additional 3,615 shares during the period. Hedge funds and other institutional investors own 60.67% of the company's stock.
Wall Street Analyst Weigh In
Several analysts recently issued reports on LXEO shares. Chardan Capital reaffirmed a "buy" rating and set a $17.00 price objective on shares of Lexeo Therapeutics in a research note on Monday, May 11th. Wall Street Zen raised shares of Lexeo Therapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, May 16th. Finally, Weiss Ratings raised shares of Lexeo Therapeutics from a "sell (e+)" rating to a "sell (d-)" rating in a research note on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, seven have issued a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Lexeo Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $18.88.
Read Our Latest Stock Analysis on LXEO
About Lexeo Therapeutics
(
Get Free Report)
Lexeo Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to developing novel, precision‐designed therapies for central nervous system disorders. The company’s research platform leverages advanced medicinal chemistry to create next‐generation psychedelic-inspired compounds aimed at treating a range of mental health conditions, including anxiety, depression and substance use disorders.
The company’s pipeline features proprietary synthetic molecules engineered to target specific neural pathways while improving safety and tolerability profiles over traditional treatments.
See Also
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
